rheumatology research
Recently Published Documents





Paula Alba Moreyra ◽  
Francis Berenbaum ◽  
Debashish Danda ◽  
Bettina Grötsch ◽  
Simon R. Stones ◽  

2021 ◽  
Joshua B. Bilsborrow ◽  
Ingris Peláez‐Ballestas ◽  
Bernardo Pons‐Estel ◽  
Christiaan Scott ◽  
Xinping Tian ◽  

2021 ◽  
Vol 19 (1) ◽  
Timothy Beukelman ◽  
Aimee Lougee ◽  
Roland A. Matsouaka ◽  
David Collier ◽  
Dax G. Rumsey ◽  

Abstract Background We aimed to characterize etanercept (ETN) use in juvenile idiopathic arthritis (JIA) patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Methods The CARRA Registry is a convenience cohort of patients with paediatric onset rheumatic diseases, including JIA. JIA patients treated with ETN for whom the month and year of ETN initiation were available were included. Patterns of ETN and methotrexate (MTX) use were categorized as follows: combination therapy (ETN and MTX started concurrently), step-up therapy (MTX started first and ETN added later), switchers (MTX started and then stopped when or before ETN started), MTX add-on (ETN started first and MTX added later), and ETN only (no MTX use). Data were described using parametric and non-parametric statistics as appropriate. Results Two thousand thirty-two of the five thousand six hundred forty-one patients with JIA met inclusion criteria (74% female, median age at diagnosis 6.0 years [interquartile range 2.0, 11.0]. Most patients (66.9%) were treated with a non-biologic disease modifying anti-rheumatic drug (DMARD), primarily MTX, prior to ETN. There was significant variability in patterns of MTX use prior to starting ETN. Step-up therapy was the most common approach. Only 34.0% of persistent oligoarticular JIA patients continued treatment with a non-biologic DMARD 3 months or more after ETN initiation. ETN persistence overall was 66.3, 49.4, and 37.3% at 24, 36 and 48 months respectively. ETN persistence among spondyloarthritis patients (enthesitis related arthritis and psoriatic JIA) varied by MTX initiation pattern, with higher ETN persistence rates in those who initiated combination therapy (68.9%) and switchers/ETN only (73.3%) patients compared to step-up (65.4%) and MTX add-on (51.1%) therapy. Conclusion This study characterizes contemporary patterns of ETN use in the CARRA Registry. Treatment was largely in keeping with American College of Rheumatology guidelines.

2021 ◽  
Vol 23 (1) ◽  
L. Boekel ◽  
F. Hooijberg ◽  
E. H. Vogelzang ◽  
P. L. Klarenbeek ◽  
W. H. Bos ◽  

AbstractClinical research projects often use traditional methods in which data collection and signing informed consent forms rely on patients’ visits to the research institutes. However, during challenging times when the medical community is in dire need of information, such as the current COVID-19 pandemic, it becomes more urgent to use digital platforms that can rapidly collect data on large numbers of patients. In the current manuscript, we describe a novel digital rheumatology research platform, consisting of almost 5000 patients with autoimmune diseases and healthy controls, that was set up rapidly during the COVID-19 pandemic, but which is sustainable for the future. Using this platform, uniform patient data can be collected via questionnaires and stored in a single database readily available for analysis. In addition, the platform facilitates two-way communication between patients and researchers, so patients become true research partners. Furthermore, blood collection via a finger prick for routine and specific laboratory measurements has been implemented in this large cohort of patients, which may not only be applicable for research settings but also for clinical care. Finally, we discuss the challenges and potential future applications of our platform, including supplying tailored information to selected patient groups and facilitation of patient recruitment for clinical trials.

2021 ◽  
Vol 3 (8) ◽  
pp. e540-e542
Su-Ann Yeoh ◽  
Barbara Burke ◽  
Madhura Castelino ◽  
Tracy Hyndman ◽  
Anne-Maree Keenan ◽  

Xavier Barber ◽  
José Alberto García-Gómez ◽  
María Paz Martínez-Vidal ◽  
Antonio Álvarez-Cienfuegos

2021 ◽  
pp. annrheumdis-2021-220478
Emilio Filippucci ◽  
Gianluca Smerilli ◽  
Andrea Di Matteo ◽  
Walter Grassi

Enthesitis has a key role in the diagnosis, classification and management of patients with spondyloarthritis and psoriatic arthritis. Clinical assessment of enthesitis is known to be inaccurate mainly due to its poor specificity. In this context, ultrasound has the potential to improve the evaluation of enthesitis and, therefore, the management of patients with spondyloarthritis and psoriatic arthritis. In this viewpoint, we review the Outcome Measures in Rheumatology (OMERACT) definitions for ultrasound enthesitis, highlighting their current limits and potential implications on rheumatology research and clinical practice.

Sign in / Sign up

Export Citation Format

Share Document